Chun‐Ming Tsai
About
Chun‐Ming Tsai is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research.
According to data from OpenAlex, Chun‐Ming Tsai has authored 114 papers receiving a total of 7.8k indexed citations (citations by other indexed papers that have themselves been cited), including 95 papers in Pulmonary and Respiratory Medicine, 84 papers in Oncology and 16 papers in Cancer Research. Recurrent topics in Chun‐Ming Tsai's work include Lung Cancer Treatments and Mutations (89 papers), Lung Cancer Research Studies (48 papers) and Lung Cancer Diagnosis and Treatment (37 papers). Chun‐Ming Tsai is often cited by papers focused on Lung Cancer Treatments and Mutations (89 papers), Lung Cancer Research Studies (48 papers) and Lung Cancer Diagnosis and Treatment (37 papers). Chun‐Ming Tsai collaborates with scholars based in Taiwan, United States and South Korea. Chun‐Ming Tsai's co-authors include James Chih‐Hsin Yang, Vera Hirsh, Tony Mok, Sumitra Thongprasert, Lecia V. Sequist, Wu‐Chou Su, Joseph S. K. Au, Sarayut Lucien Geater, Michael Boyer and Martin Schüler and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.
In The Last Decade
Chun‐Ming Tsai
111 papers receiving 7.7k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Chun‐Ming Tsai Taiwan | 31 | 6.4k | 5.3k | 2.0k | 1.4k | 417 | 114 | 7.8k | ||
| José Rodrigues Pereira Brazil | 17 | 7.0k 1.1× | 6.3k 1.2× | 2.0k 1.0× | 1.2k 0.9× | 601 1.4× | 25 | 8.7k | ||
| Ki Hyeong Lee South Korea | 39 | 7.1k 1.1× | 6.7k 1.3× | 2.1k 1.0× | 1.5k 1.1× | 560 1.3× | 196 | 9.6k | ||
| David M. Jackman United States | 38 | 5.6k 0.9× | 4.9k 0.9× | 2.0k 1.0× | 1.7k 1.2× | 388 0.9× | 87 | 7.6k | ||
| Eng Huat Tan Singapore | 22 | 4.7k 0.7× | 4.6k 0.9× | 1.7k 0.8× | 1.0k 0.7× | 732 1.8× | 55 | 6.8k | ||
| Mircea Dediu Romania | 19 | 5.1k 0.8× | 4.8k 0.9× | 1.6k 0.8× | 894 0.6× | 337 0.8× | 55 | 6.6k | ||
| Alessandro Morabito Italy | 40 | 3.4k 0.5× | 4.8k 0.9× | 1.7k 0.8× | 1.7k 1.2× | 443 1.1× | 217 | 7.2k | ||
| Renato Martins United States | 20 | 4.7k 0.7× | 4.6k 0.9× | 1.7k 0.8× | 916 0.6× | 363 0.9× | 42 | 6.7k | ||
| Akira Inoue Japan | 37 | 5.5k 0.9× | 5.0k 0.9× | 1.8k 0.9× | 930 0.7× | 357 0.9× | 193 | 7.1k | ||
| Rogério Lilenbaum United States | 33 | 5.5k 0.9× | 5.6k 1.1× | 2.1k 1.0× | 1.2k 0.9× | 473 1.1× | 105 | 8.4k | ||
| B. Findlay Canada | 25 | 4.8k 0.8× | 7.0k 1.3× | 1.7k 0.8× | 1.5k 1.0× | 895 2.1× | 44 | 9.1k |
Countries citing papers authored by Chun‐Ming Tsai
Since
Specialization
Citations
This map shows the geographic impact of Chun‐Ming Tsai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chun‐Ming Tsai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chun‐Ming Tsai more than expected).
Fields of papers citing papers by Chun‐Ming Tsai
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Chun‐Ming Tsai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chun‐Ming Tsai. The network helps show where Chun‐Ming Tsai may publish in the future.
Co-authorship network of co-authors of Chun‐Ming Tsai
This figure shows the co-authorship network connecting the top 25 collaborators of Chun‐Ming Tsai. A scholar is included among the top collaborators of Chun‐Ming Tsai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chun‐Ming Tsai. Chun‐Ming Tsai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Tsai, Chun‐Ming, Luc Cabel, Enrico Moiso, et al.. (2024). 418P Concordance of PI3K-AKT pathway alterations between tumor and ctDNA in metastatic breast cancer. Annals of Oncology. 35. S395–S396.
2.
Ho, Hsiang‐Ling, Yuqiu Jiang, Chi‐Lu Chiang, et al.. (2022). Efficacy of liquid biopsy for disease monitoring and early prediction of tumor progression in EGFR mutation-positive non-small cell lung cancer. PLoS ONE. 17(4). e0267362–e0267362.
3.
Ho, Hsiang‐Ling, Fangyu Wang, Chi‐Lu Chiang, et al.. (2022). Dynamic Assessment of Tissue and Plasma EGFR-Activating and T790M Mutations with Droplet Digital PCR Assays for Monitoring Response and Resistance in Non-Small Cell Lung Cancers Treated with EGFR-TKIs. International Journal of Molecular Sciences. 23(19). 11353–11353.
4.
Huang, Chien‐Sheng, Hui‐Shan Chen, Po‐Kuei Hsu, et al.. (2021). Sequence for Surgical Resection of Primary Lung Tumor for Oligometastatic Non-small Cell Lung Cancer. The Annals of Thoracic Surgery. 113(4). 1333–1340.
5.
Castro, Gilberto de, Daniel Shao-Weng Tan, Lucio Crinò, et al.. (2017). PL03.07: First-line Ceritinib Versus Chemotherapy in Patients with ALK-rearranged (ALK+) NSCLC: A Randomized, Phase 3 Study (ASCEND-4). Journal of Thoracic Oncology. 12(1). S7–S7.
6.
Tan, Daniel Shao-Weng, Jean‐Charles Soria, Gilberto de Castro, et al.. (2017). P3.02a-025 PROs With Ceritinib Versus Chemotherapy in Patients With Previously Untreated ALK-rearranged Nonsquamous NSCLC (ASCEND-4). Journal of Thoracic Oncology. 12(1). S1176–S1177.
7.
Fein, Luis, Yi‐Long Wu, Lecia V. Sequist, et al.. (2016). P1.33: Afatinib Versus Chemotherapy for EGFR Mutation-Positive NSCLC Patients Aged ≥65 Years: Subgroup Analysis of LUX-Lung 3/6. Journal of Thoracic Oncology. 11(10). S202–S203.
8.
Chen, Hung-Ming, et al.. (2015). Concomitant Primary Lung Cancer and Metastatic Pulmonary Colorectal Cancer that Responded to Gemcitabine/Cisplatin/Bevacizumab Combination Therapy. SHILAP Revista de lepidopterología.
9.
Boye, Mark E., Xin Wang, Vichien Srimuninnimit, et al.. (2015). First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-cell Lung Cancer: Quality of Life Results From a Randomized Phase III Trial. Clinical Lung Cancer. 17(2). 150–160.
10.
Sequist, Lecia V., James Chih‐Hsin Yang, Nobuyuki Yamamoto, et al.. (2013). Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations. Journal of Clinical Oncology. 31(27). 3327–3334.
11.
Chiu, Chao‐Hua, Yi‐Chen Yeh, Ko-Han Lin, et al.. (2011). Histological Subtypes of Lung Adenocarcinoma Have Differential 18F-Fluorodeoxyglucose Uptakes on the Positron Emission Tomography/Computed Tomography Scan. Journal of Thoracic Oncology. 6(10). 1697–1703.
12.
Chen, Yuh‐Min, et al.. (2010). Second-Line Therapy for Elderly Patients with Non-small Cell Lung Cancer Who Failed Previous Chemotherapy Is as Effective as for Younger Patients. Journal of Thoracic Oncology. 5(3). 376–379.
13.
Chen, Yuh‐Min, Jen-Fu Shih, Chun‐Ming Tsai, et al.. (2009). Revisiting Squamous Cell Carcinoma of the Lungs-A Disease Given Less Attention. 25(6). 393–402.
14.
Chang, Gee‐Chen, Chun‐Ming Tsai, Kun‐Chieh Chen, et al.. (2006). Predictive Factors of Gefitinib Antitumor Activity in East Asian Advanced Non-small Cell Lung Cancer Patients. Journal of Thoracic Oncology. 1(6). 520–525.
15.
Lai, Chun‐Liang, Chun‐Ming Tsai, Chao‐Hua Chiu, et al.. (2005). Phase II Randomized Trial of Tri-weekly Versus Days 1 and 8 Weekly Docetaxel as a Second-line Treatment of Advanced Non-small Cell Lung Cancer. Japanese Journal of Clinical Oncology. 35(12). 700–706.
16.
Chen, Yuh‐Min, Chun‐Ming Tsai, Jacqueline Whang‐Peng, & Reury-Perng Perng. (2001). Interleukin-7 and Interleukin-12 Have Different Effects in Rescue of Depressed Cellular Immunity: Comparison of Malignant and Tuberculous Pleural Effusions. Journal of Interferon & Cytokine Research. 21(4). 249–256.
17.
Tsai, Chun‐Ming, et al.. (2000). Interrelationships between Cellular Nucleotide Excision Repair, Cisplatin Cytotoxicity, HER‐2/neu Gene Expression, and Epidermal Growth Factor Receptor Level in Non‐small Cell Lung Cancer Cells. Japanese Journal of Cancer Research. 91(2). 213–222.
18.
Tsai, Chun‐Ming, et al.. (1996). Enhancement of chemosensitivity by tyrphostin AG825 in high-p185(neu) expressing non-small cell lung cancer cells.. PubMed. 56(5). 1068–74.
19.
Chen, Yuh-Min, et al.. (1995). Elevation of Serum Interleukin-6 Levels Before Peak of Serum Granulocyte Colony-Stimulating Factor Level in Chemotherapy-Induced Myelosuppressive Patients. Journal of Immunotherapy. 17(4). 249–254.
20.
Tsai, Chun‐Ming, et al.. (1990). Enhancement of fluorinated pyrimidine‐induced cytotoxicity by leucovorin in human lung cancer cell lines. International Journal of Cancer. 46(1). 101–105.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by José Rodrigues Pereira Breakdown of academic impact, for papers by Ki Hyeong Lee Breakdown of academic impact, for papers by David M. Jackman Breakdown of academic impact, for papers by Eng Huat Tan Breakdown of academic impact, for papers by Mircea Dediu Breakdown of academic impact, for papers by Alessandro Morabito Breakdown of academic impact, for papers by Renato Martins Breakdown of academic impact, for papers by Akira Inoue Breakdown of academic impact, for papers by Rogério Lilenbaum Breakdown of academic impact, for papers by B. Findlay